Table 3 Haplotype distribution in colorectal cancer patients and normal controls
From: GSTT2 promoter polymorphisms and colorectal cancer risk
Haplotype | Frequecy | Distribution | Healthy control (N = 568) | CRC patients (N = 436) | p | OR(95% CI) |
|---|---|---|---|---|---|---|
HT1 (G-T-G) | 0.511 | non-HT1/non-HT1 | 140 (24.6%) | 99 (22.7%) | 0.336 | 1.160 (0.857–1.571) |
| Â | Â | HT1/non-HT1 or HT1/HT1 | 428 (75.4%) | 337 (77.3%) | Â | Â |
HT2 (A-T-G) | 0.422 | non-HT2/non-HT2 | 204 (35.9%) | 127 (29.1%) | 0.021 | 1.386 (1.052–1.828) |
| Â | Â | HT2/non-HT2 or HT2/HT2 | 364 (64.1%) | 309 (70.9%) | Â | Â |
HT3 (G-C-G) | 0.033 | non-HT3/non-HT3 | 532 (93.7%) | 405 (92.9%) | 0.984 | 0.995 (0.595–1.663) |
| Â | Â | HT3/non-HT3 | 36 (6.3%) | 31 (7.1) | Â | Â |
HT4 (G-C-A) | 0.032 | non-HT4/non-HT4 | 522 (91.9%) | 416 (95.4%) | 0.032 | 0.539 (0.307–0.947) |
| Â | Â | HT4/non-HT4 | 46 (8.1%) | 20 (4.6%) | Â | Â |